Explore real-world tirzepatide dosage trends, reconstitution data, and mixing patterns from 20,000+ anonymized peptide calculator entries at World Peptide Association.
Built from 20,000+ anonymized calculator inputs, this data reveals how researchers approach tirzepatide reconstitution—typical weekly dose selections, vial sizes, and bacteriostatic water volumes used with this dual GIP/GLP-1 receptor agonist.
The two biggest tirzepatide studies most researchers reference are SURPASS-2 and SURMOUNT-1, both published in the New England Journal of Medicine. SURPASS-2 enrolled 1,879 people across four groups—three tirzepatide doses and a semaglutide comparison arm—giving around 470 participants per dose group over a 40-week period. SURMOUNT-1 was larger: 2,539 participants across four groups (roughly 630 per arm), followed for 72 weeks. In both studies, everyone started at 2.5mg per week for the first four weeks as a required titration step before escalating—but the doses actually being evaluated long-term were 5mg, 10mg, and 15mg. No major trial has studied what sustained use at 2.5mg looks like.
Tirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro and Zepbound, and the research peptide most often sourced for weight-management and metabolic studies. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Tirzepatide engages both incretin receptors simultaneously, slowing gastric emptying, reducing post-prandial glucose excursions, lowering glucagon, and amplifying glucose-dependent insulin secretion. The shared GIP arm appears to add weight-loss efficacy that pure GLP-1 agonists do not match, although the precise contribution of GIP signalling remains an active area of investigation.
The SURPASS program established A1C reductions of roughly 2.0–2.4% in type 2 diabetes at 5–15mg weekly, and SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported mean weight reduction of ~20.9% at 72 weeks on the 15mg arm. Active trials extend tirzepatide into heart failure with preserved ejection fraction (SUMMIT), obstructive sleep apnea (SURMOUNT-OSA), and metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH).
Tirzepatide has a reported half-life of ~5 days, and the dose intervals researchers model most often fall around once weekly. Once-weekly dosing reaches steady state in about 4 weeks. Missing a dose by a day is fine; missing by 4+ days drops you well below your usual range. It is catalogued under Weight Loss on WPA.
13,560 Tirzepatide reconstitution calculations have been logged by the WPA community. The most common dose entered is 2.5mg (2,923 calculations). The median dose across all sessions is 5mg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 30mg (3,552 sessions). The most common dosing frequency is once weekly (1,511 logged protocols), followed by daily (7x/week) (91).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.